title: Food, fibre, bile acids and the pelvic floor: An integrated low risk low cost approach to managing irritable bowel syndrome.
abstract: Patients presenting with abdominal pain and diarrhea are often labelled as suffering from irritable bowel syndrome, and medications may be used often without success. Advances in the understanding of the causes of the symptoms (including pelvic floor weakness and incontinence, bile salt malabsorption and food intolerance) mean that effective, safe and well tolerated treatments are now available.
authors.affiliation: Hamish Philpott, Sanjay Nandurkar, John Lubel, Peter R Gibson, Monash University, Eastern Health, The Alfred Hospital, Melbourne 3128, Australia.
authors.forename: Hamish
authors.initials: H
authors.lastname: Philpott
authors.affiliation: Hamish Philpott, Sanjay Nandurkar, John Lubel, Peter R Gibson, Monash University, Eastern Health, The Alfred Hospital, Melbourne 3128, Australia.
authors.forename: Sanjay
authors.initials: S
authors.lastname: Nandurkar
authors.affiliation: Hamish Philpott, Sanjay Nandurkar, John Lubel, Peter R Gibson, Monash University, Eastern Health, The Alfred Hospital, Melbourne 3128, Australia.
authors.forename: John
authors.initials: J
authors.lastname: Lubel
authors.affiliation: Hamish Philpott, Sanjay Nandurkar, John Lubel, Peter R Gibson, Monash University, Eastern Health, The Alfred Hospital, Melbourne 3128, Australia.
authors.forename: Peter R
authors.initials: PR
authors.lastname: Gibson
mesh_terms: D015746:Abdominal Pain / Q000503:physiopathology / Q000628:therapy; D001647:Bile Acids and Salts / Q000378:metabolism*; D003967:Diarrhea / Q000503:physiopathology / Q000628:therapy; D050528:Diet, Carbohydrate-Restricted / Q000191:economics; D004040:Dietary Carbohydrates / Q000009:adverse effects* / Q000378:metabolism; D004043:Dietary Fiber / Q000008:administration & dosage* / Q000191:economics / Q000378:metabolism; D005242:Fecal Incontinence / Q000503:physiopathology / Q000628:therapy; D017048:Health Care Costs; D006801:Humans; D007408:Intestinal Absorption; D007413:Intestinal Mucosa / Q000378:metabolism; D007422:Intestines / Q000503:physiopathology*; D043183:Irritable Bowel Syndrome / Q000191:economics / Q000378:metabolism / Q000503:physiopathology / Q000628:therapy*; D008286:Malabsorption Syndromes / Q000191:economics / Q000378:metabolism / Q000503:physiopathology / Q000628:therapy*; D017773:Pelvic Floor / Q000503:physiopathology*; D064449:Sequestering Agents / Q000191:economics / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D001647:Bile Acids and Salts; D004040:Dietary Carbohydrates; D004043:Dietary Fiber; D064449:Sequestering Agents
keywords: Bile acids; Diarrhoea; Food intolerance; Irritable bowel syndrome; Pelvic floor